ASCO
Liquid Biopsy Firms Eye Melanoma for Minimal Residual Disease Testing, Though Questions Remain
Premium
MRD assays show promise in immunotherapy response prediction with the potential to guide dose/treatment escalation with emerging adjuvant approaches.
In Brief This Week: CAP, T2 Biosystems, Siemens Healthineers, DiaSorin, More
News items for the week of June 5, 2023.
Personalized Residual Disease Assays Show Promise to Overcome Liquid Biopsy Challenges in Sarcomas
Premium
New data presented at the ASCO annual meeting this week showed that tumor-informed assays could detect emerging recurrence ahead of imaging.
Early Adopters Share Experiences With Grail Cancer Test as Firm Faces New Clinical Questions
Premium
Real-world and trial data shored up evidence that the company's multi-cancer detection assay can guide follow-up assessment of patients with a positive result.
The company believes the new results, from an initial prospective multisite trial, reflect what it can achieve in the larger cohort that it is now planning to recruit.
Aug 8, 2022
Jun 4, 2021
Jun 13, 2019